South Korean drug manufacturer JW Pharmaceutical has completed a Phase I clinical trial of CWP 291, a new drug developed for the treatment of various cancers including acute myeloid leukemia.
Judging that the safety of the drug has been sufficiently proven, JW Pharmaceutical now plans to move onto the next phase: expanding the use of the drug to treat other types of cancer, such as head and neck cancer and stomach cancer.
JW Pharmaceutical notified its shareholders on May 2 that 69 people with acute myeloid leukemia took the drug in its Phase I clinical trial of CWP 291 until December last year.
JW Pharmaceutical said: “The maximum tolerated dose (MTD) was determined in the Phase I clinical trial of CWP 291. The MTD was previously estimated at 100mg/m² in pre-clinical testing. The Phase I clinical trial, however, showed that the MTD was more than twice as high as the estimated 100mg/m². It was 250mg/m².”
The fact that the MTD well exceeded the estimated 100mg/m² indicates that the safety of the drug has been fully assured.
Backed by the results of the Phase I clinical trial of CWP 291, JW Pharmaceutical is now planning to expand the use of the drug to treat solid cancer like head and neck cancer, stomach cancer, ovarian cancer and breast cancer.